Elanco Animal Health Incorporated ELAN NYSE

Elanco Animal Health Incorporated (ELAN) generated $560M in operating cash flow for fiscal year 2025. After capital expenditures of $276M, free cash flow was $284M.

Free cash flow margin was 6% of revenue. Cash conversion ratio was -2.41x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was -2.41x suggests some earnings are non-cash items

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.